In conclusion, our study revealed that SIRT5 deficiency in cultured ADMSCs switches their metabolic pattern to a state that more resembles that of the cells in the in vivo microenvironment, which leads to enhanced self‐renewal capacities and improved therapeutic functions for ischemic disease treatment. The gene discussed is SIRT5; the disease is ischemic disease.